Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Apr;37(4):769–774. doi: 10.1128/aac.37.4.769

Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

K Nagata 1, H Satoh 1, T Iwahi 1, T Shimoyama 1, T Tamura 1
PMCID: PMC187756  PMID: 8494373

Abstract

The gastric proton pump inhibitor lansoprazole, its active analog AG-2000, and omeprazole dose dependently inhibited urease activity extracted with distilled water from Helicobacter pylori cells; the 50% inhibitory concentrations were between 3.6 and 9.5 microM, which were more potent than those of urease inhibitors, such as acetohydroxamic acid, hydroxyurea, and thiourea. These compounds also inhibited urease activity in intact cells of H. pylori and Helicobacter mustelae but did not inhibit ureases from other bacteria, such as Proteus vulgaris, Proteus mirabilis, and Providencia rettgeri. The mechanism of urease inhibition was considered to be blockage of the SH groups of H. pylori urease, since SH residues in the enzyme decreased after preincubation with lansoprazole and glutathione or dithiothreitol completely abolished the inhibitory action. The SH-blocking reagents N-ethylmaleimide and idoacetamide were also examined for their inhibition of the urease activity; their 50% inhibitory concentrations were 100- to 1,000-fold higher than those of lansoprazole. These results suggest that lansoprazole and omeprazole can potently and selectively inhibit H. pylori urease and that inhibition may be related to earlier findings indicating that these compounds have selective activity against HP growth.

Full text

PDF
769

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barer M. R., Elliott T. S., Berkeley D., Thomas J. E., Eastham E. J. Cytopathic effects of Campylobacter pylori urease. J Clin Pathol. 1988 May;41(5):597–597. doi: 10.1136/jcp.41.5.597-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bayerdörffer E., Oertel H., Lehn N., Kasper G., Mannes G. A., Sauerbruch T., Stolte M. Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol. 1989 Aug;42(8):834–839. doi: 10.1136/jcp.42.8.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Biasco G., Miglioli M., Barbara L., Corinaldesi R., di Febo G. Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer. Lancet. 1989 Dec 9;2(8676):1403–1403. doi: 10.1016/s0140-6736(89)92021-7. [DOI] [PubMed] [Google Scholar]
  4. Bode G., Malfertheiner P., Nilius M., Lehnhardt G., Ditschuneit H. Ultrastructural localisation of urease in outer membrane and periplasm of Campylobacter pylori. J Clin Pathol. 1989 Jul;42(7):778–779. doi: 10.1136/jcp.42.7.778-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buck G. E. Campylobacter pylori and gastroduodenal disease. Clin Microbiol Rev. 1990 Jan;3(1):1–12. doi: 10.1128/cmr.3.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cellini L., Marzio L., Di Girolamo A., Allocati N., Grossi L., Dainelli B. Enhanced clearing of Helicobacter pylori after omeprazole plus roxithromycin treatment. FEMS Microbiol Lett. 1991 Dec 1;68(3):255–257. doi: 10.1016/0378-1097(91)90365-h. [DOI] [PubMed] [Google Scholar]
  7. Clayton C. L., Pallen M. J., Kleanthous H., Wren B. W., Tabaqchali S. Nucleotide sequence of two genes from Helicobacter pylori encoding for urease subunits. Nucleic Acids Res. 1990 Jan 25;18(2):362–362. doi: 10.1093/nar/18.2.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dunn B. E., Perez-Perez G. I., Blaser M. J. Two-dimensional gel electrophoresis and immunoblotting of Campylobacter pylori proteins. Infect Immun. 1989 Jun;57(6):1825–1833. doi: 10.1128/iai.57.6.1825-1833.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. ELLMAN G. L. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959 May;82(1):70–77. doi: 10.1016/0003-9861(59)90090-6. [DOI] [PubMed] [Google Scholar]
  10. Ferrero R. L., Cussac V., Courcoux P., Labigne A. Construction of isogenic urease-negative mutants of Helicobacter pylori by allelic exchange. J Bacteriol. 1992 Jul;174(13):4212–4217. doi: 10.1128/jb.174.13.4212-4217.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Glupczynski Y., Labbe M., Burette A., Delmee M., Avesani V., Bruck C. Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet. 1987 May 9;1(8541):1096–1096. doi: 10.1016/s0140-6736(87)90527-7. [DOI] [PubMed] [Google Scholar]
  12. Graham D. Y. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):615–625. doi: 10.1016/s0016-5085(89)80057-5. [DOI] [PubMed] [Google Scholar]
  13. Hawtin P. R., Stacey A. R., Newell D. G. Investigation of the structure and localization of the urease of Helicobacter pylori using monoclonal antibodies. J Gen Microbiol. 1990 Oct;136(10):1995–2000. doi: 10.1099/00221287-136-10-1995. [DOI] [PubMed] [Google Scholar]
  14. Hazell S. L., Lee A. Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers. Lancet. 1986 Jul 5;2(8497):15–17. doi: 10.1016/s0140-6736(86)92561-4. [DOI] [PubMed] [Google Scholar]
  15. Helander H. F., Ramsay C. H., Regårdh C. G. Localization of omeprazole and metabolites in the mouse. Scand J Gastroenterol Suppl. 1985;108:95–104. doi: 10.3109/00365528509095822. [DOI] [PubMed] [Google Scholar]
  16. Hu L. T., Mobley H. L. Purification and N-terminal analysis of urease from Helicobacter pylori. Infect Immun. 1990 Apr;58(4):992–998. doi: 10.1128/iai.58.4.992-998.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Inouye H., Yamamoto I., Tanida N., Mikami J., Tamura K., Ohno T., Kano M., Shimoyama T. Campylobacter pylori in Japan: bacteriological feature and prevalence in healthy subjects and patients with gastroduodenal disorders. Gastroenterol Jpn. 1989 Oct;24(5):494–504. doi: 10.1007/BF02773875. [DOI] [PubMed] [Google Scholar]
  18. Iwahi T., Satoh H., Nakao M., Iwasaki T., Yamazaki T., Kubo K., Tamura T., Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991 Mar;35(3):490–496. doi: 10.1128/aac.35.3.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Labigne A., Cussac V., Courcoux P. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity. J Bacteriol. 1991 Mar;173(6):1920–1931. doi: 10.1128/jb.173.6.1920-1931.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lindberg P., Nordberg P., Alminger T., Brändström A., Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem. 1986 Aug;29(8):1327–1329. doi: 10.1021/jm00158a001. [DOI] [PubMed] [Google Scholar]
  21. Marshall B. J. Campylobacter pyloridis and gastritis. J Infect Dis. 1986 Apr;153(4):650–657. doi: 10.1093/infdis/153.4.650. [DOI] [PubMed] [Google Scholar]
  22. Marshall B. J., Warren J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984 Jun 16;1(8390):1311–1315. doi: 10.1016/s0140-6736(84)91816-6. [DOI] [PubMed] [Google Scholar]
  23. McNulty C. A., Gearty J. C., Crump B., Davis M., Donovan I. A., Melikian V., Lister D. M., Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986 Sep 13;293(6548):645–649. doi: 10.1136/bmj.293.6548.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mertens J. C., Dekker W., Ligtvoet E. E., Blok P. Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia. Antimicrob Agents Chemother. 1989 Feb;33(2):256–257. doi: 10.1128/aac.33.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mobley H. L., Cortesia M. J., Rosenthal L. E., Jones B. D. Characterization of urease from Campylobacter pylori. J Clin Microbiol. 1988 May;26(5):831–836. doi: 10.1128/jcm.26.5.831-836.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Morii M., Takata H., Takeguchi N. Binding site of omeprazole in hog gastric H+,K(+)-ATPase. Biochem Biophys Res Commun. 1990 Mar 16;167(2):754–760. doi: 10.1016/0006-291x(90)92089-i. [DOI] [PubMed] [Google Scholar]
  27. Nagata K., Mizuta T., Tonokatu Y., Fukuda Y., Okamura H., Hayashi T., Shimoyama T., Tamura T. Monoclonal antibodies against the native urease of Helicobacter pylori: synergistic inhibition of urease activity by monoclonal antibody combinations. Infect Immun. 1992 Nov;60(11):4826–4831. doi: 10.1128/iai.60.11.4826-4831.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nagaya H., Satoh H., Kubo K., Maki Y. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther. 1989 Feb;248(2):799–805. [PubMed] [Google Scholar]
  29. Price A. B. Histological aspects of Campylobacter pylori colonisation and infection of gastric and duodenal mucosa. Scand J Gastroenterol Suppl. 1988;142:21–24. [PubMed] [Google Scholar]
  30. Pérez-Pérez G. I., Olivares A. Z., Cover T. L., Blaser M. J. Characteristics of Helicobacter pylori variants selected for urease deficiency. Infect Immun. 1992 Sep;60(9):3658–3663. doi: 10.1128/iai.60.9.3658-3663.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sachs G., Munson K., Balaji V. N., Aures-Fischer D., Hersey S. J., Hall K. Functional domains of the gastric HK ATPase. J Bioenerg Biomembr. 1989 Oct;21(5):573–588. doi: 10.1007/BF00808114. [DOI] [PubMed] [Google Scholar]
  32. Satoh H., Inatomi N., Nagaya H., Inada I., Nohara A., Nakamura N., Maki Y. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther. 1989 Feb;248(2):806–815. [PubMed] [Google Scholar]
  33. Smoot D. T., Mobley H. L., Chippendale G. R., Lewison J. F., Resau J. H. Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infect Immun. 1990 Jun;58(6):1992–1994. doi: 10.1128/iai.58.6.1992-1994.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Stone J. W., Wise R., Donovan I. A., Gearty J. Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach. J Antimicrob Chemother. 1988 Jul;22(1):92–93. doi: 10.1093/jac/22.1.92. [DOI] [PubMed] [Google Scholar]
  35. Unge P., Gnarpe H. Pharmacokinetic, bacteriological and clinical aspects on the use of doxycycline in patients with active duodenal ulcer associated with Campylobacter pylori. Scand J Infect Dis Suppl. 1988;53:70–73. [PubMed] [Google Scholar]
  36. Van Caekenberghe D. L., Breyssens J. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother. 1987 Sep;31(9):1429–1430. doi: 10.1128/aac.31.9.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wallmark B., Brändström A., Larsson H. Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell. Biochim Biophys Acta. 1984 Dec 19;778(3):549–558. doi: 10.1016/0005-2736(84)90406-1. [DOI] [PubMed] [Google Scholar]
  38. Xu J. K., Goodwin C. S., Cooper M., Robinson J. Intracellular vacuolization caused by the urease of Helicobacter pylori. J Infect Dis. 1990 Jun;161(6):1302–1304. doi: 10.1093/infdis/161.6.1302. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES